Vaxcyte

vaccine diversity flu covid shot needle
Biotech

Vaxcyte surges on 'stunning' 31-valent PCV win against Pfizer

Vaxcyte unveiled what analysts called “stunning” phase 1/2 data for its 31-valent pneumococcal vaccine candidate.
Angus Liu Sep 3, 2024 10:32am
snow mountain winter

BioMarin CEO replaces commercial chief—Chutes & Ladders

Jan 19, 2024 8:30am
US dollar bills scattered on a yellow background undefined undefinedGetty Images

Pivotal bioVenture Partners unveils $389M fund

Dec 18, 2023 7:00am
investment money shot vaccine pharma dollar

Blackstone, Sutro ink royalty pact worth up to $390M biobucks

Jun 26, 2023 1:47pm
Photo of a syringe and two vials labeled pneumococcal vaccine

Vaxcyte's pneumococcal shot holds its own against Prevnar

Apr 17, 2023 11:10am